High GBP1 expression inhibited tumor cell proliferation in breast and colorectal cancers (Lipnik et al., 2010; Britzen-Laurent et al., 2013), but it was strongly associated with disease progression and paclitaxel resistance in ovarian cancer and glioblastoma (Li et al., 2011; Wadi et al., 2016). Here, GBP1 is linked to ovarian cancer.